Medtronic's defining moves.
The defining strategic moves at Medtronic — each one explained and grounded in the record.
The Adjacency Expansion · Adjacency Expansion
Medtronic Bought Its Way Into Everything. The Market Just Asked It to Stop.
Medtronic ran 71 acquisitions to build the broadest portfolio in standalone medtech. Then it spun out diabetes at a $5.29B valuation — below range — and a decade of stock returns came in at ~17%. Breadth built scale; it didn't build value.
8 min
The Moat Anatomy · Competitive Moats
Medtronic Has a Real Moat. The Problem Is It Isn't Earning Anything From It.
Everyone calls Medtronic a wide-moat fortress with tens of thousands of patents. But its return on invested capital is 6.74% against a market at 11.03% - a moat that defends a plateau instead of compounding from one.
8 min
The Market-Entry Gambit · Market Entry
Medtronic Didn't Buy a Company. It Bought a Postcode.
Medtronic spent roughly $50 billion to acquire Covidien in 2015 - the largest tax inversion in U.S. history. The device portfolio was the cover story. The real asset was an Irish legal address that unlocked ~$13 billion of trapped offshore cash.
8 min